Shopping Cart 0
Cart Subtotal
USD 0

Recurrent Medulloblastoma Global Clinical Trials Review, H1, 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Recurrent Medulloblastoma Global Clinical Trials Review, H1, 2018

Summary

GlobalData's clinical trial report, Recurrent Medulloblastoma Global Clinical Trials Review, H1, 2018" provides an overview of Recurrent Medulloblastoma clinical trials scenario. This report provides top line data relating to the clinical trials on Recurrent Medulloblastoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Report Guidance 4

GlobalData Clinical Trials Report Coverage 5

Clinical Trials by Region 6

Clinical Trials and Average Enrollment by Country 7

Top Countries Contributing to Clinical Trials in Asia-Pacific 9

Top Five Countries Contributing to Clinical Trials in Europe 10

Top Countries Contributing to Clinical Trials in North America 11

Clinical Trials by G7 Countries: Proportion of Recurrent Medulloblastoma to Oncology Clinical Trials 12

Clinical Trials by Phase in G7 Countries 13

Clinical Trials in G7 Countries by Trial Status 14

Clinical Trials by Phase 15

In Progress Trials by Phase 16

Clinical Trials by Trial Status 17

Clinical Trials by End Point Status 18

Subjects Recruited Over a Period of Time 19

Clinical Trials by Sponsor Type 20

Prominent Sponsors 21

Top Companies Participating in Recurrent Medulloblastoma Therapeutics Clinical Trials 22

Prominent Drugs 23

Clinical Trial Profile Snapshots 24

Appendix 49

Abbreviations 49

Definitions 49

Research Methodology 50

Secondary Research 50

About GlobalData 51

Contact Us 51

Disclaimer 51

Source 52


List Of Figure

List of Figures

Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials by Region (%), 2018* 6

Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 7

Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 8

Recurrent Medulloblastoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2018* 9

Recurrent Medulloblastoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 10

Recurrent Medulloblastoma Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 11

Proportion of Recurrent Medulloblastoma to Oncology Clinical Trials, G7 Countries (%), 2018* 12

Recurrent Medulloblastoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 13

Recurrent Medulloblastoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 14

Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials by Phase (%), 2018* 15

Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 16

Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials by Trial Status, 2018* 17

Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, by End Point Status, 2018* 18

Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 19

Recurrent Medulloblastoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 20

Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 21

Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 22

Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 23

GlobalData Methodology 50


List Of Table

List of Tables

Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials by Region, 2018* 6

Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 7

Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 8

Recurrent Medulloblastoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2018* 9

Recurrent Medulloblastoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 10

Recurrent Medulloblastoma Therapeutics Clinical Trials, North America, Top Countries, 2018* 11

Proportion of Recurrent Medulloblastoma to Oncology Clinical Trials, G7 Countries (%), 2018* 12

Recurrent Medulloblastoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 13

Recurrent Medulloblastoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 14

Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials by Phase, 2018* 15

Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 16

Recurrent Medulloblastoma Therapeutics, Global, Clinical Trials by Trial Status, 2018* 17

Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, by End Point Status, 2018* 18

Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 19

Recurrent Medulloblastoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 20

Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 21

Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 22

Recurrent Medulloblastoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 23

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Recurrent Medulloblastoma Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Recurrent Medulloblastoma, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania


Companies

Novartis AG

F. Hoffmann-La Roche Ltd

Eli Lilly and Co

E. Merck KG

Dynamic Science SL

Cytokinetics Inc

Celgene Corp

Bristol-Myers Squibb Co

Annias Immunotherapeutics Inc

AbbVie Inc